At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRBP Corbus Pharmaceuticals
Not Yet Opened 05-17 16:00:00 EDT
45.00
-0.92
-2.00%
盘后45.00
+0.000.00%
19:47 EDT
High46.22
Low43.63
Vol123.94K
Open45.81
D1 Closing45.92
Amplitude5.64%
Mkt Cap472.83M
Tradable Cap304.94M
Total Shares10.51M
T/O5.58M
T/O Rate1.83%
Tradable Shares6.78M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Google DeepMind CEO: ‘This Is the Next $100 Billion AI Business’
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.